Biogen Inc. (BIIB): Price and Financial Metrics


Biogen Inc. (BIIB)

Today's Latest Price: $265.00 USD

1.80 (-0.67%)

Updated Oct 23 4:00pm

Add BIIB to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

BIIB Stock Summary

  • With a market capitalization of $42,572,075,487, Biogen Inc has a greater market value than 95.32% of US stocks.
  • BIIB's current price/earnings ratio is 7.18, which is higher than just 9.49% of US stocks with positive earnings.
  • In terms of volatility of its share price, BIIB is more volatile than only 2.53% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Biogen Inc, a group of peers worth examining would be KLAC, ADI, GLW, ERIC, and GRMN.
  • BIIB's SEC filings can be seen here. And to visit Biogen Inc's official web site, go to www.biogen.com.

BIIB Stock Price Chart Interactive Chart >

Price chart for BIIB

BIIB Price/Volume Stats

Current price $265.00 52-week high $374.99
Prev. close $266.80 52-week low $257.60
Day low $262.17 Volume 1,016,100
Day high $267.23 Avg. volume 1,653,703
50-day MA $278.50 Dividend yield N/A
200-day MA $293.04 Market Cap 40.78B

Biogen Inc. (BIIB) Company Bio


Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. The company was founded in 1985 and is based in Cambridge, Massachusetts.


BIIB Latest News Stream


Event/Time News Detail
Loading, please wait...

BIIB Latest Social Stream


Loading social stream, please wait...

View Full BIIB Social Stream

Latest BIIB News From Around the Web

Below are the latest news stories about Biogen Inc that investors may wish to consider to help them evaluate BIIB as an investment opportunity.

STAT Plus: The biotech scorecard for the fourth quarter: 18 stock-moving events to watch

Before Covid-19 came along, there was nothing that loomed larger in biotech than aducanumab, Biogen’s controversial treatment for Alzheimer’s disease.

STAT News | October 1, 2020

Multiple Sclerosis Market to 2027 Report on Industry Insights, Market Overview, Top Company Players-Pfizer, Sanofi, Novartis AG, F. Hoffmann-La Roche Ltd, Biogen, Bayer AG, Actelion Pharmaceuticals Ltd

Global Multiple Sclerosis Market Research Report best suits the requirements of the client. The report represents a basic overview of the Multiple Sclerosis market share, competitor segment with a basic introduction of key vendors, top regions, product types, and end

OpenPR | September 30, 2020

FDA OKs Cipla's generic version of Biogen's Tecfidera

The FDA approves Mumbai, India-based Cipla Limited's generic version of Biogen's (BIIB) top-selling multiple sclerosis med Tecfidera (dimethyl fumarate).Last month, Mylan launched its version.Tecfidera accounted for 32% of Biogen's Q2 sales....

Seeking Alpha | September 28, 2020

Biogen loses appeal in patent dispute over multiple sclerosis drug

Biogen ([[BIIB]] +3.1%) comes up empty in its appeal of a lower court ruling invalidating a key patent covering beta-interferon, its multiple sclerosis med branded as Avonex (interferon beta-1a).It was seeking billions in royalties from Merck KGaA (MKGAY) related to its MS med Rebif (interferon beta-1a).The U.S. Court of Appeals...

Seeking Alpha | September 28, 2020

Merck, Pfizer prevail in patent fight with Biogen over multiple sclerosis drug

A federal appeals court on Monday invalidated a Biogen Inc patent on the treatment of multiple sclerosis using a protein known as interferon-beta, a victory for Merck & Co and Pfizer Inc, which jointly market the interferon-beta-based drug Rebif.

Reuters | September 28, 2020

Read More 'BIIB' Stories Here

BIIB Price Returns

1-mo -3.03%
3-mo -5.48%
6-mo -13.03%
1-year -8.00%
3-year -13.89%
5-year -2.04%
YTD -10.69%
2019 -1.39%
2018 -5.54%
2017 21.96%
2016 -7.43%
2015 -9.75%

Continue Researching BIIB

Want to see what other sources are saying about Biogen Inc's financials and stock price? Try the links below:

Biogen Inc (BIIB) Stock Price | Nasdaq
Biogen Inc (BIIB) Stock Quote, History and News - Yahoo Finance
Biogen Inc (BIIB) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7068 seconds.